Sweden · Series B startup

Who invested in Gesynta Pharma

One round we have observed, with the 8 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechFemtechPharma

Funding summaryUpdated 26 Oct 2026

$27Mraised across 1 round since 2025, from 2 sources

Latest round
Series B, $27MJan 2025
Investors
8
See who backed them

The rounds

  1. Jan 2025

Everyone who backed them

IndustrifondenVC firm1round
InnovestorAngel network1round
Hadean VenturesPrivate equity1round
Foreground CapitalVC firm1round
Catalyze CapitalGrowth equity1round
Stephen IndustriesFamily office1round
LincGrowth equity1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists Gesynta Pharma as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.

HealthCapVC firmPer its own site

Quick answers about Gesynta Pharma

Who invested in Gesynta Pharma?

Gesynta Pharma's investors include Industrifonden, Innovestor, Amboy Street Ventures, Hadean Ventures and Foreground Capital, and 3 more on record.

How much has Gesynta Pharma raised?

Gesynta Pharma has raised $27M across 1 round since 2025.

When did Gesynta Pharma last raise?

Gesynta Pharma's most recent round was a Series B of $27M in Jan 2025.

What was Gesynta Pharma's biggest round?

Its most recent round, $27M in Jan 2025, is also its largest on record.

Who backed Gesynta Pharma first?

Gesynta Pharma's first round on record, in Jan 2025, was backed by Industrifonden, Innovestor and Amboy Street Ventures and 5 others.

What stage is Gesynta Pharma at?

Gesynta Pharma's latest named round is a Series B, in Jan 2025.

Where is Gesynta Pharma based?

Gesynta Pharma is based in Sweden.

Companies like Gesynta Pharma

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.